Thomas McCoy Roberts, Ph.D.
This page shows the publications Thomas Roberts has written about Antineoplastic Agents.
Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 2013 Jan; 3(1):44-51.
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 07; 22(7):723-6.
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug; 8(8):627-44.
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene. 2020 01; 39(1):50-63.
PI3 kinase alpha and delta promote hematopoietic stem cell activation. JCI Insight. 2019 05 23; 5.
Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol. 2009 Apr; 21(2):199-208.
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.